Israeli company CytoReason announced last night that it had signed a licensing agreement with Sanofi to use its artificial intelligence tools to discover new drugs.

The project aims to exploit CytoReason's artificial intelligence cell models to identify patient subtypes for the treatment of inflammatory bowel diseases.

Under the terms of this multi-year agreement, CytoReason will receive several million dollars from Sanofi.

This is an extension of the collaboration between the two groups, which have been working together since 2021 to better understand the heterogeneity of asthma patients.

CytoReason's platform, based on gene expression information, feeds bibliographic data to create a model for target, biomarker and drug response discovery, and indication selection.

Copyright (c) 2023 CercleFinance.com. All rights reserved.